A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07192614 by AstraZeneca, with 52 participants planned, started 2025-09-30 and due to reach its primary completion in 2029-03-29. Interventions recorded: AZD6621. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.